BioCentury
ARTICLE | Finance

Double vision

NuCana's $57M enough to get pivotal data for lead cancer program

April 14, 2014 7:00 AM UTC

Sofinnova Ventures led NuCana BioMed Ltd.'s $57 million B round in the hopes its founders can once again bring a nucleoside-based cancer therapy to market.

NuCana's ProTide technology adds a phosphoramidate moiety to oncologic nucleosides to improve their activity and safety. The company's Acelarin (NUC-1031) is a ProTide of gemcitabine that is in Phase I testing...